Intuitive Surgical shows no slowing
This article was originally published in The Gray Sheet
Executive Summary
Growth of robotic surgery systems firm continues to soar with second quarter sales of $87 mil., up 65% from the prior-year period, driven by strong performance from Intuitive Surgical's gynecologic sector, which became its second largest surgical segment. Hysterectomy was the fastest growing procedure, VP-Business Development & Strategic Planning Aleks Cukic noted during firm's Q2 earnings call July 26. The largest gainer two years running on "The Gray Sheet" OTC index, Intuitive shipped 39 of its million-dollar-plus da Vinci systems during the quarter, bringing the number of worldwide installations to 467 (1"The Gray Sheet" Jan. 23, 2006, p. 13)...
You may also be interested in...
NuVasive Boosts Artificial Disc Development, Stock; OTC Index Rises 15%
NuVasive will use profits gained from a series of 510(k)-cleared spinal devices to fuel artificial disc and nucleus replacement development in 2006
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.